Trial Profile
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648/TAK-648 in healthy Japanese volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2020
Price :
$35
*
At a glance
- Drugs TAK 648 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- 12 Oct 2020 Status changed from recruiting to completed.
- 14 Apr 2020 Planned number of patients changed from 32 to 44.
- 14 Apr 2020 Planned End Date changed from 31 Mar 2020 to 31 Dec 2020.